Tekmira Pharmaceuticals Corporation  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
13.96
-2.24 (-13.83%)
Apr 15 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 12.59 - 16.99
52 week 4.55 - 34.66
Open 16.21
Vol / Avg. 613,872.00/142,742.00
Mkt cap 304.53M
P/E     -
Div/yield     -
EPS -1.01
Shares 21.81M
Beta 0.36
Inst. own     -
Mar 24, 2014
Q4 2013 Tekmira Pharmaceuticals Corporation Earnings Release (Estimated)
Feb 11, 2014
Tekmira Pharmaceuticals Corporation at Biotechnology Industry Organization CEO & Investor Conference
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -34.35% -90.95%
Operating margin -31.82% -78.59%
EBITD margin - -74.63%
Return on average assets -17.53% -22.63%
Return on average equity -22.67% -28.10%
Employees 85 -
CDP Score - -

Address

Suite 100, 8900 Glenlyon Parkway
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

Description

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.

Officers and directors

Daniel L. Kisner M.D. Independent Chairman of the Board
Age: 66
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Ian MacLachlan Ph.D. Executive Vice President, Chief Technical Officer
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 51
Paul A. Brennan Senior Vice President - Business Development
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 57
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
Diane Gardiner Vice President - Human Resources
R. Hector MacKay-Dunn Q.C. Corporate Secretary